Роль цитокинов в диагностике хронического простатита


Цитировать

Полный текст

Аннотация

Chronic prostatitis affects 30-60% males and significantly deteriorates quality of their life. Clinical and experimental investigations have revealed changes in immune status in the onset and development of prostatic inflammation. As some other urologists, we made an attempt to determine the role of cellular immunity and immunoglobulins in the diagnosis of chronic prostatitis. The study was made in 30 patients with chronic abacterial prostatitis (mean age 42.5 years, duration of the disease 1.8 years). In addition to standard examination, all the patients have undergone analysis of the immune status and measurement of proinflammatory cytokines (TNFa and IL-12b) in biological media: blood serum, urine, ejaculate, prostatic secretion. The patients had moderate symptoms: IPSS - 10.4 scores, life quality index - 4.3 scores, on the average. Prostamol-uno was given to all the patients in a standard dose 1 capsule (320 mg) a day for 3 to 6 months. The results were processed statistically. A good effect of prostamoluno was registered in 26 patients, a satisfactory one - in 2. Two patients refused to take prostamol-uno because of lack of a prominent effect. The scores of IPSS lowered from 10.4 to 6.3 (by 39%), life quality improved by 42%. Ultrasound monitoring of the size of the prostate showed no significant changes in the size. Tolerance was good in all 30 patients. Side effects were absent. After 3 months of the treatment serum, urine, ejaculate and prostatic secretion cytokines changed. TNFa elevated while IL-ip level lowered almost to normal value. In 6 months both IL-ip and TNFa returned to normal values confirming stabilization of cytokine system and the end of inflammation. Cellular immunity did not change much. Thus, as inflammation in prostatic tissue is characterized by elevation of proinflammatory cytokines, in diagnosis of chronic prostatitis it will be valid to use markers TNFa and IL-ip as criteria of immune prognosis of prostatic exacerbation. Prostamol-uno does not induce changes in lymphocyte populations and impairment of immune status.

Об авторах

С В Разумов

НИИ урологии Минздрава РФ

Москва; НИИ урологии Минздрава РФ

А А Медведев

НИИ урологии Минздрава РФ

Москва; НИИ урологии Минздрава РФ

Н В Чирун

НИИ урологии Минздрава РФ

Москва; НИИ урологии Минздрава РФ

А В Сивков

НИИ урологии Минздрава РФ

Москва; НИИ урологии Минздрава РФ

В Н Ощепков

НИИ урологии Минздрава РФ

Москва; НИИ урологии Минздрава РФ

В Н Синюхин

НИИ урологии Минздрава РФ

Москва; НИИ урологии Минздрава РФ

Список литературы

  1. Лопаткин Н. А. (ред.) Доброкачественная гиперплазия предстательной железы. М.; 1997.
  2. Textbook of benign prostatic hyperplasia; 1996.233-340.
  3. Berry S. J., Coffey D. A., Walsh P. S. et al. The development of human benign prostatic hyperplasia with age. J. Urol. (Baltimore) 1984; 132: 474-479.
  4. Alexander R. В., Ponniah S., Hasday J., Hebel R. J. Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/ chronic pelvic pain sydrome. Urology 1998; 52(5): 744-749.
  5. Nadler R. В., Koch A. E., Calhoun E. A. et al. IL-1R and TNFa in prostatic secretions are indicators in the evaluation of men with chronic prostatitis. J. Urol. (Baltimore) 2000; 164: 214- 218.
  6. Аль-Шукри С. X., Бобков Ю. А., Галкина О. В. и др. Иммуноглобулин Е при хроническом простатите. Урология 2001; 5: 12-14.
  7. Kramer G., Steiner G., Lee C., Marberger M. Intracellular cytokine expression pattern of prostatic T-lymphocytes. In: XVI-Hth European association of urology congress. Madrid; 2003. A-66.
  8. Vela-Navarrete R., Garcia-Cardoso J., Barat A. et al. Effects of the lipido sterolic extract of serenoa repens (Permixon) on infiltrating cells and inflammatory markers in prostatic tissues from BPH patients // XVIIth European association of urology congress. Birmingham; 2000. A-238.
  9. Reissigl A., Pointner J., Djavan B. et al. Multi centre study to evaluate the safety and efficacy of phytotherapeuticum Permixon in the treatment of chronic prostatitis/ chronic pelvic pain sydrome // XVIIth European association of urology congress. Madrid; 2003. A-49.
  10. Ebralidze D., Kochiashvili D. Blood profile of interleukin-4 and gamma-interferon in patients with benign prostatic hyperplasia. Ibid. A-69.
  11. Colins M. M., McDonald R., Wilt T. J. Diagnosis and treatment of chronic abacterial prostatitis: a systematic rewiew. Ann. Intern. Med. 2000; 133: 367-381.
  12. Wagner H. et al. Uber ein neues antiphlogistischcs Wirkprinzip aus Sabal serrulata. Planta Med. 1981; 41 (3): 244-251.
  13. Tarayre J. P. et al. Action anti-oedemateuse d'un extrait hexanique de drupes de Serenoa repens B. Ann. Pharm. Franc. 1983; 41 (6): 559-570.
  14. Lobelenz J. Extractum Sabal fructus in the therapy of benign prostatic hyperplasia (BPH). Therapeuticon. Spec. Reprint 1992; 6: 34-37.
  15. Koch E., Biber A. Pharmakologische Wirkungen von Sabal and Urtica-Extrakten als Grundlage fur eine rationale medikamentose Therapie der benigen Prostata hyperplasie. Urologe 1994; В 34: 90-95.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах